Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 1/20 | 0.51 |
| ▸ | MDM4 | O15151 | 3/20 | 0.49 |
| ▸ | TP53 | P04637 | 3/20 | 0.49 |
| ▸ | MDM2 | Q00987 | 4/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.43 |
| ▸ | CCKAR | P32238 | 2/20 | 0.43 |
| ▸ | CCKBR | P32239 | 2/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30917941 | 1.00 | ADAM17 (0.51) | ADAM17MDM4TP53MDM2L3MBTL1 | |
| SCHEMBL5969202 | 1.00 | ADAM17 (0.51) | ADAM17MDM4TP53MDM2L3MBTL1 | |
| SCHEMBL1000833 | 1.00 | ADAM17 (0.51) | ADAM17MDM4TP53MDM2L3MBTL1 | |
| SCHEMBL29364320 | 1.00 | ADAM17 (0.51) | ADAM17MDM4TP53MDM2L3MBTL1 | |
| SCHEMBL1709188 | 1.00 | ADAM17 (0.51) | ADAM17MDM4TP53MDM2L3MBTL1 | |
| SCHEMBL12052757 | 0.93 | L3MBTL1 (0.48) | ADAM17MDM4TP53MDM2L3MBTL1 | |
| SCHEMBL8104292 | 0.93 | L3MBTL1 (0.48) | ADAM17MDM4TP53MDM2L3MBTL1 | |
| SCHEMBL30231797 | 0.93 | ADAM17 (0.51) | ADAM17MDM4TP53MDM2L3MBTL1 | |
| SCHEMBL119657 | 0.92 | MDM4 (0.53) | MDM4TP53MDM2SLC17A5 | |
| SCHEMBL120776 | 0.92 | MDM4 (0.53) | MDM4TP53MDM2SLC17A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1476 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116854-A1 | METHOD FOR PREPARING FMOC-TRP(BOC)-OH | SICHUAN SHIFANG SANGAO BIOCHEMICAL INDUSTRIAL CO., LTD. (CN) | 2026-04-30 | — | — | US | claimed |
| US-20260116848-A1 | Synthesis of an Intermediate and Its Use for the Preparation of GLP-1R/GIPR Agonists | CARMOT THERAPEUTICS INC. (US) | 2026-04-30 | — | — | US | claimed |
| US-12600759-B2 | Process of preparation of glucagon-like peptide-1 (GLP-1) receptor agonists and their analogs | ENZENE BIOSCIENCES LIMITED (IN) | 2026-04-14 | — | — | US | claimed |
| CN-121574188-A | Application of donkey-source bioactive peptide and its derivative in cosmetics | 上海湃肽生物科技有限公司 | 2026-02-27 | — | — | CN | claimed |
| US-12503486-B2 | Compound or salt thereof and preparation method and application of same | ZHEJIANG PEPTITES BIOTECH CO., LTD. (CN) | 2025-12-23 | — | — | US | claimed |
| US-20250326796-A1 | PEPTIDE ANALOG WITH ANTI-INFLAMMATORY ACTIVITY AND ITS PREPARATION METHOD AND APPLICATION | SHANGHAI UNIVERSITY (CN) | 2025-10-23 | — | — | US | claimed |
| US-20250236655-A1 | PROCESS FOR THE PREPARATION OF LIRAGLUTIDE | SHILPA PHARMA LIFESCIENCES LIMITED (IN) | 2025-07-24 | — | — | US | claimed |
| WO-2025130972-A1 | SYNTHETIC METHOD FOR TIRZEPATIDE | 深圳翰宇药业股份有限公司 | 2025-06-26 | — | — | WO | claimed |
| US-20250205372-A1 | RADIOPHARMACEUTICAL COMPOSITIONS, SYNTHETIC METHODS, AND METHODS OF TREATMENT | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2025-06-26 | — | — | US | claimed |
| CN-120081899-A | Multifunctional self-assembled short peptide ZT48, preparation method and application thereof, and short peptide ZT48 self-assembled body | 常州市智态生创科技有限公司 | 2025-06-03 | — | — | CN | claimed |
| CN-114276415-A | Method for synthesizing leuprorelin by solid-liquid method | 湖南三太药业有限公司 | 2022-04-05 | — | — | CN | claimed |
| CN-114249810-A | Synthetic method of somaglutide | 深圳翰宇药业股份有限公司 | 2022-03-29 | — | — | CN | claimed |
| CN-114014912-B | Method for preparing leuprorelin by combining solid phase and liquid phase | 浙江湃肽生物有限公司南京分公司 | 2022-03-29 | — | — | CN | claimed |
| CN-114230637-A | Method for synthesizing deslorelin by solid and liquid | 湖南三太药业有限公司 | 2022-03-25 | — | — | CN | claimed |
| CN-114181285-A | Method for synthesizing nafarelin by solid-liquid method | 湖南三太药业有限公司 | 2022-03-15 | — | — | CN | claimed |
| CN-110294800-B | Preparation method of somaglutide | 齐鲁制药有限公司 | 2022-03-04 | — | — | CN | claimed |
| CN-113880921-B | Synthetic method of bremer langdan acetate | 浙江湃肽生物有限公司南京分公司 | 2022-02-18 | — | — | CN | claimed |
| CN-114014912-A | Method for preparing leuprorelin by combining solid phase and liquid phase | 浙江湃肽生物有限公司南京分公司 | 2022-02-08 | — | — | CN | claimed |
| CN-113651875-B | Oligopeptide-34 synthesis method | 南京莱昂生物科技有限公司 | 2022-01-28 | — | — | CN | claimed |
| EP-3941936-A2 | PROCESS OF PREPARATION OF GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS AND THEIR ANALOGS | Enzene Biosciences Ltd. (IN) | 2022-01-26 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260116848-A1 | Synthesis of an Intermediate and Its Use for the Preparation of GLP-1R/GIPR Agonists | GLP1R, GIPR, CCKBR | ADAM17 3958/4885MDM4 4227/4885TP53 4727/4885 |
| US-20260116854-A1 | METHOD FOR PREPARING FMOC-TRP(BOC)-OH | TPH1, TPH2, TYR | ADAM17 1654/4885MDM4 1112/4885TP53 2692/4885 |
| US-20250236655-A1 | PROCESS FOR THE PREPARATION OF LIRAGLUTIDE | GLP1R, IAPP, VIP | ADAM17 1927/4885MDM4 1231/4885TP53 4366/4885 |
| US-20250326796-A1 | PEPTIDE ANALOG WITH ANTI-INFLAMMATORY ACTIVITY AND ITS PREPARATION METHOD AND APPLICATION | STING1, CGAS, VIP | ADAM17 303/4885MDM4 1661/4885TP53 1709/4885 |
| US-20250205372-A1 | RADIOPHARMACEUTICAL COMPOSITIONS, SYNTHETIC METHODS, AND METHODS OF TREATMENT | QPCT, SSTR5, SSTR4 | ADAM17 4131/4885MDM4 1815/4885TP53 494/4885 |
| US-12503486-B2 | Compound or salt thereof and preparation method and application of same | SEM1, REN, SETDB1 | ADAM17 2512/4885MDM4 4729/4885TP53 4748/4885 |
| US-12600759-B2 | Process of preparation of glucagon-like peptide-1 (GLP-1) receptor agonists and their analogs | GLP1R, GIPR, GCG | ADAM17 1798/4885MDM4 3864/4885TP53 4243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.